Da Ren Tang Expands Presence in Singapore with 5 New Products

Singapore subsidiary of Da Ren Tang recently announced another achievement, having successfully obtained registration certificates for 6 Chinese proprietary medicines, including Qinggong Shoutao Pills. This marks another significant milestone for the company in the Southeast Asian market, following the approval of 12 product registrations in 2024.

The newly added products include: Qinggong Shoutao Pills, Wuji Baifeng Tablets, Huoxiang Zhengqi Oral Liquid, Shixiao Pills, Liuwei Dihuang Pills, and Hawthorn Pills. This expansion further enriches Da Ren Tang’s portfolio of Chinese proprietary medicines in Singapore, covering areas such as common disease management and health preservation, and demonstrates its commitment to providing high-quality TCM services to meet overseas health needs.

As a pioneer in the global expansion of TCM, Tianjin Pharma Da Ren Tang has consistently driven the internationalization of its products with high standards, strictly adhering to local regulations while integrating traditional wisdom with modern technology. The consecutive breakthroughs in registering Chinese proprietary medicines in Singapore demonstrate the brand's strength and inject new momentum into its deep cultivation of the Southeast Asian market. In the future, the company will continue to leverage innovation as a driving force, making TCM benefits accessible globally.